Plasma Amyloid-Beta Stabilization for Alzheimer's Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing Alzheimer's disease are inaccurate and unreliable, particularly in living patients, as they rely on costly imaging technologies and cannot effectively differentiate between Alzheimer's and Mild Cognitive Impairment, and there are no approved tests for pre-diagnosis, with Aβ in blood being challenging to detect due to its aggregation with Human Serum Albumin and degradation by proteases.
Innovation Solution
A method involving a plasma pretreatment composition of protease and phosphatase inhibitors (MPP) to stabilize Aβ42 and Aβ40, allowing for their accurate measurement in plasma, which can predict cognitive decline and diagnose Alzheimer's disease by comparing concentrations to normal controls, potentially replacing the need for PET scans.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If Aβ is measured in blood plasma, then diagnostic information can be obtained, but Aβ aggregation with Human Serum Albumin and degradation by proteases prevents accurate detection
Solution Approach 1:
The patent applies preliminary action by adding protease inhibitors and phosphatase inhibitors to the plasma sample before Aβ measurement. This预处理 prevents protease degradation and phosphatase-mediated aggregation of Aβ prior to detection, ensuring accurate measurement by addressing harmful factors before they can affect the target molecule
Solution Approach 2:
The patent uses protease inhibitors and phosphatase inhibitors as intermediary substances that mediate between the harmful enzymatic activities and the Aβ molecules. These inhibitors act as protective intermediaries that block the harmful interactions without directly interacting with Aβ itself, allowing accurate detection to proceed
2Measurement precision
If PiB-PET imaging is used to detect Aβ accumulation in the brain, then diagnostic accuracy is improved, but the cost becomes prohibitively high
Solution Approach 1:
The patent replaces expensive PiB-PET imaging with a low-cost plasma-based diagnostic test. By using readily available plasma samples and simple biochemical assays with protease and phosphatase inhibitors, the method achieves comparable diagnostic accuracy at a fraction of the cost, making Alzheimer's diagnosis accessible to broader populations
Solution Approach 2:
The patent creates a surrogate diagnostic system that copies the functional information obtained from PiB-PET imaging but through a different, cheaper medium. Instead of imaging Aβ directly in the brain using expensive radiotracers, the method measures Aβ concentration in plasma as a surrogate marker, providing equivalent diagnostic value at lower cost
3Ease of operation
If current clinical diagnosis methods are used, then diagnosis can be performed, but they cannot reliably differentiate Alzheimer's disease from Mild Cognitive Impairment
Solution Approach 1:
The patent improves disease differentiation by measuring and comparing specific parameters (Aβ42, Aβ40, and their ratio) in plasma samples. By establishing reference ranges and diagnostic thresholds for these parameters, the method enables reliable differentiation between Alzheimer's disease and Mild Cognitive Impairment while maintaining ease of operation through simple plasma assays
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method provides a reliable and cost-effective means to diagnose and predict Alzheimer's disease by stabilizing Aβ in plasma, allowing for accurate detection and differentiation from Mild Cognitive Impairment, thereby improving diagnostic accuracy and reducing the reliance on expensive imaging technologies.
Implementation Method 1
treating a plasma sample with MPP (Mixture of protease inhibitors and phosphatase inhibitors)
Implementation Method 2
treating a plasma sample with MPP (Mixture of protease inhibitors and phosphatase inhibitors)
Implementation Method 3
treating a plasma sample with MPP (Mixture of protease inhibitors and phosphatase inhibitors) and/or TCEP
Data Source
AI summary
Provided is a method for quantifying Aβ in plasma by treating the plasma with MPP and/or TCEP, and a method for diagnosing, using the quantifying method, whether or not clinical cognitive deterioration and pathological Aβ accumulation occur. Through cut-off values of measured values measured by the method for quantifying Aβ according to the present subject matter, it is possible to identify normal, MCI and AD subjects and determine whether or not accumulation of Aβ in the brain occurs, and it is possible to predict progression to AD.